Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Novartis' Exjade Receives Approval From The European Commission

RELATED NEWS
Trade NVS now with 
12/21/2012 1:45 AM ET

Novartis AG (NVS: Quote) Friday said it has received approval from the European Commission for Exjade, an oral drug used to subside iron overload in patients undergoing chelation therapy for non-transfusion-dependent thalassemia, or NTDT, syndrome.

The approval is based on results from the placebo-controlled study of iron chelation in NTDT patients.

Thalassemia is a genetic disorder affecting red blood cell production, and thereby causing anemia. NTDT, unlike many other types of thalassemia, don't receive regular transfusion, subsequently resulting in a chronic iron overload.

Certain other health complication including liver fibrosis and cirrhosis, blood clots, bone disease, pulmonary hypertension, can also lead to higher iron concentration.

At least three quarters of a million people worldwide have NTDT syndromes, according to published studies.

In the pivotal study, named THALASSA, Exjade showed a significant dose-dependent decrease in concentration of iron-burden in the body as well as liver, compared to placebo. Meanwhile, the overall adverse event rate for Exjade was similar to the placebo arm.

Click here to receive FREE breaking news email alerts for Novartis AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Reserve Bank of New Zealand on Thursday raised its Official Cash Rate by 25 basis points, to 3.00 percent from 2.75 percent. The decision was in line with expectations, and it marks the second straight month with a rate hike following 24 straight meetings in which the rate was not changed. New Zealand's economic expansion has considerable momentum, with GDP estimated to have grown by 3.5 percent in the year to March. Apple Inc. said Wednesday after the markets closed that its second quarter profit rose 7% from last year, as sales surged and margins improved amid strong sales of its iPhones. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue. At the same time, the company gave a slightly downbeat revenue forecast for the current quarter. Stocks moved mostly lower during trading on Wednesday, giving back some ground after trending higher over the past several sessions. Selling pressure was relatively subdued, however, limiting the downside for the markets. The major averages all closed in the red, although the tech-heavy Nasdaq underperformed its counterparts by a wide margin.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.